Conduit Pharmaceuticals Inc (CDT) Stock Price, Quote & News

Company Profile

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility...

Industry: Biotechnology

Sector: Healthcare

Phone: (646)-491-9132

Website: www.conduitpharma.com

Address:

4581 Tamiami Trail North, Suite 200, Naples, United States

MrShubby Aug. 21 at 4:57 PM

$CDT anybody out there except this new account opened on 8/18/25 from a short or a disgruntled long that bailed? I have a feeling I know who it is……

4 · Reply

CeciliaS Aug. 21 at 4:30 PM

$CDT stinky....!

0 · Reply

MrShubby Aug. 20 at 11:26 PM

$CDT

1 · Reply

MrShubby Aug. 20 at 8:49 PM

$CDT

1 · Reply

Bears2354 Aug. 20 at 8:34 PM

$CDT did we finish in the green today ? Haha wtf 😳

0 · Reply

LOSERTOTHECORE Aug. 20 at 8:18 PM

$PRPH and $CDT WORST STOCKS @Stocktwits Kick these out of Stock market!!!! Bloody RED SEA SHORT SHORT SHORT SINCE THE START WHILE $SPY MAKES HIGHER HIGHS ALL THE TIME 💦

1 · Reply

Nevilhch Aug. 20 at 2:27 PM

$CDT Well, friends, this has overwhelmed me. I don't want to fall into the slump of lost costs. Accept the losses and move on. I won't wait for that moment, which is getting delayed more and more, and every day there's less hope that it will actually happen. Sayonara, good luck to everyone who recovers their money

2 · Reply

samba1008 Aug. 20 at 2:01 PM

$CDT low after low it breaks its own records.. Fed up bros.

0 · Reply

Nevilhch Aug. 20 at 10:06 AM

$CDT Good morning, shit lovers. Here we are, keeping shit for another day for a change, jejejej

0 · Reply

MrShubby Aug. 19 at 10:38 PM

$CDT https://www.cdtequity.com/news-events/press-releases/

1 · Reply

Conduit to Change Name to CDT Equity Inc.

Jul 8, 2025, 8:30 AM EDT - 6 weeks ago

Conduit Engages Consultant to Explore Cryptocurrency Reserve Strategy

Jul 7, 2025, 8:30 AM EDT - 6 weeks ago

Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries

Jun 4, 2025, 8:30 AM EDT - 2 months ago

Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health

May 22, 2025, 8:30 AM EDT - 3 months ago

Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market

May 21, 2025, 8:30 AM EDT - 3 months ago

Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance

May 16, 2025, 8:30 AM EDT - 3 months ago

Conduit Pharmaceuticals Inc. Announces Reverse Stock Split

May 9, 2025, 8:30 AM EDT - 3 months ago

Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

May 8, 2025, 8:30 AM EDT - 3 months ago

Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset

Apr 16, 2025, 8:30 AM EDT - 4 months ago

Conduit Pharmaceuticals Announces Leadership Changes

Apr 11, 2025, 8:30 AM EDT - 4 months ago

Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects

Mar 31, 2025, 8:30 AM EDT - 5 months ago

Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Mar 19, 2025, 8:30 AM EDT - 5 months ago

Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904

Mar 6, 2025, 9:35 AM EST - 6 months ago

Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel

Feb 20, 2025, 8:00 AM EST - 6 months ago

Conduit Progresses Phase II of its AI Initiative with Sarborg

Feb 13, 2025, 8:00 AM EST - 6 months ago

Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model

Feb 11, 2025, 9:00 AM EST - 6 months ago

Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note

Feb 7, 2025, 8:00 AM EST - 7 months ago

Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development

Jan 28, 2025, 5:30 AM EST - 7 months ago

Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence

Dec 12, 2024, 7:30 AM EST - 9 months ago

Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics

Nov 21, 2024, 7:30 AM EST - 9 months ago

Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders

Nov 19, 2024, 4:30 PM EST - 9 months ago

Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Nov 4, 2024, 7:30 AM EST - 10 months ago

Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline

Nov 1, 2024, 4:45 PM EDT - 10 months ago

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

May 22, 2024, 7:00 AM EDT - 1 year ago

AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024

AZN

Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO

May 21, 2024, 8:00 AM EDT - 1 year ago

4 · Reply

CeciliaS Aug. 21 at 4:30 PM

$CDT stinky....!

0 · Reply

MrShubby Aug. 20 at 11:26 PM

$CDT

1 · Reply

MrShubby Aug. 20 at 8:49 PM

$CDT

1 · Reply

Bears2354 Aug. 20 at 8:34 PM

$CDT did we finish in the green today ? Haha wtf 😳

0 · Reply

LOSERTOTHECORE Aug. 20 at 8:18 PM

$PRPH and $CDT WORST STOCKS @Stocktwits Kick these out of Stock market!!!! Bloody RED SEA SHORT SHORT SHORT SINCE THE START WHILE $SPY MAKES HIGHER HIGHS ALL THE TIME 💦

1 · Reply

Nevilhch Aug. 20 at 2:27 PM

2 · Reply

samba1008 Aug. 20 at 2:01 PM

$CDT low after low it breaks its own records.. Fed up bros.

0 · Reply

Nevilhch Aug. 20 at 10:06 AM

$CDT Good morning, shit lovers. Here we are, keeping shit for another day for a change, jejejej

0 · Reply

MrShubby Aug. 19 at 10:38 PM

$CDT https://www.cdtequity.com/news-events/press-releases/

1 · Reply

DORO879 Aug. 19 at 10:21 PM

$CDT

0 · Reply

DORO879 Aug. 19 at 10:17 PM

$CDT new website nothing for press release look the old news is gone.

1 · Reply

Nevilhch Aug. 19 at 8:48 PM

$CDT This shit has no bottom

1 · Reply

DipnRiptrader Aug. 19 at 7:24 PM

$CDT 😬

0 · Reply

MrShubby Aug. 19 at 6:59 PM

$CDT adding

2 · Reply

East_Saxon2 Aug. 19 at 6:57 PM

$CDT .4’s ↗️

0 · Reply

MrShubby Aug. 19 at 4:56 PM

$CDT

2 · Reply

DipnRiptrader Aug. 19 at 4:50 PM

$CDT damn another low.

0 · Reply

Nevilhch Aug. 19 at 3:17 PM

$CDT r/s soon

2 · Reply

Wealthy93 Aug. 19 at 2:51 PM

$CDT needs volume unfortunately. I’ll put it on my watchlist

0 · Reply

Nevilhch Aug. 19 at 10:13 AM

$CDT

0 · Reply

FerretsOfWallStreet Aug. 19 at 10:09 AM

$CDT

0 · Reply

Market Cap	5.41M
Revenue (ttm)	0.00
Net Income (ttm)	-17.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	109,702
Avg Vol	422,744
Day's Range	N/A - N/A
Shares Out	2.93M
Stochastic %K	5%
Beta	1.93
Analysts	Strong Buy
Price Target	N/A

Conduit Pharmaceuticals Inc (CDT)

Company Profile

Conduit to Change Name to CDT Equity Inc.

Conduit Engages Consultant to Explore Cryptocurrency Reserve Strategy

Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries

Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health

Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market

Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance

Conduit Pharmaceuticals Inc. Announces Reverse Stock Split

Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset

Conduit Pharmaceuticals Announces Leadership Changes

Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects

Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904

Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel

Conduit Progresses Phase II of its AI Initiative with Sarborg

Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model

Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note

Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development

Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence

Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics

Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders

Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024

Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO

Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe's Leading Life Sciences Hub

Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Conduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare Conference

Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656

ClinConnect Partners with Conduit Pharmaceuticals on Cocrystal Development Program for AZD1656

Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination